Salgena is an exclusive immunotherapy developed by Hope4Cancer’s own Dr. Tony Jimenez in collaboration with scientific collaborators in Germany and Mexico. Comprised of three key components: (1) injectable thymus and epithalon peptides, (2) oral immune support, and (3) the Salvus Immunotherapy protocol, this 13-week protocol enhances the cellular immune system and encourages the body’s natural ability to detect and kill cancer cells.
Known as the hub of the immune system, the thymus gland is responsible for forming and training T-cells, the lymphocytes that identify cancer cells and alert the immune system to their dangerous presence. Unfortunately, thymus size and functioning deteriorates rapidly with age, leading to a natural decay in immune defense. Thymus peptide therapy helps to reverse this process and enhance protection from disease.
Epithalon is a tetrapeptide that increases activity of the enzyme telomerase. Telomerase works to repair shortened telomeres, the “protective caps” located on the end of chromosomes. These caps safeguard healthy cells, but are worn down significantly with age, increasing the risk of disease. By stimulating telomerase and lengthening telomeres, epithalon peptides inhibit tumor development, increase lymph flow, and prevent metastasis.
The second component of the Salgena protocol involves Activa IC3, an oral immune nutraceutical. By combining the benefits of four synergistic ingredients, Activa IC3 stimulates and regulates the population of dendritic cells, increases the production of immune cell lines, and ensures the presence of larger dendritic cell populations with desirable characteristics.
The four key ingredients and functions of Activa IC3 are:
- Shark cartilage: Acts as an anti-angiogenic agent to disrupt tumors’ ability to form new blood vessels
- Resveratrol: Polyphenolic compound found in grapes, red wine, berries, and peanuts with a number of anticancer benefits and the potential to decrease tumor volume and prevent metastasis.
- Graviola: Inhibits ATP production and interferes with reproduction of cancer cells.
- Curcumin: Therapeutic agent with antioxidative and anti-inflammatory properties.
The final component of Salgena is the Salvus Immunotherapy protocol. Salvus plays a critical role in increasing numbers and activation status of dendritic cells, the messenger cells that educate our adaptive immune system to attack cancer. Cancer suppresses dendritic cell activation, which makes them unable to transfer essential antigen information to T-cells, and the immune system continues to lie dormant. By activating dendritic cells, Salvus helps to activate the adaptive immune system and provides a powerful immune boost that targets the cancer cells.
Overall, the Salgena program works through multiple mechanisms to achieve a number of anticancer, antiaging, and immunomodulating health benefits. Salgena is most effective when used as part of a comprehensive treatment program derived from the 7 Key Principles of Cancer Therapy.
- Thymic peptides for treatment of cancer patients. Cochrane Systematic
- Patent WO2016195468: Strengthened T-Cell Modulator than can modulate the
immune response, specifically designed for therapeutic use for the treatment of the
disease known as vitiligo.
- Patent WO2013058640: Method for the extraction, verification and counting of
dialyzed leukocyte extract originating from shark spleen in order to obtain
potentialized transfer factor, specifically designed for use as treatment against the
disease known asthma.
- Patent WO2016195470: Potentiated T-cell modulator able to modulate immune
response, method for extracting, testing and counting a dialysable leukocyte
extract from shark spleen to produce same, and therapeutic use thereof.
- Certifications from SAGARPA (Ministry of Agriculture and Rural Development)
and SEMARNAT (Ministry of Environment and Natural Resources) in Mexico
that establish that the gray shark is not considered endangered and can be lawfully
- Palucka K, Banchereau J (2013) Dendritic-cell-based therapeutic cancer vaccines.
Immunity 39, 38-48.
- Nestle FO (2000) Dendritic cell vaccination for cancer therapy. Oncogene 19,
- Santos PM, Butterfield LH (2018) Dendritic cell-based cancer vaccines. J.
Immunol. 200, 443-449.
- Papewalis C, Ehlers M, Schott M (2010) Advances in cellular therapy for the
treatment of thyroid cancer. J. Oncol. Article ID 179491, 11 pages.
- Van de Laar L, Coffer PJ (2012) Regulation of dendritic cell development by GMCSF:
molecular control and implications for immune homeostasis and therapy.
Blood 119, 3383-3393.
- Cancer Pain Management with a Venom of Blue Scorpion Endemic in Cuba,
Called Rhopalurus Junceus “ Escozul”, Di Lorenzo L.*,1, Palmieri Chiara2 ,
Cusano Antonio1 and Foti Calogero1, 1Rehabilitation Unit Rummo BN Hospital
Doctorate Program, Rehab Med Tor Vergata University, Rome, Italy 2Campus
Biomedico Oncology, University of Rome, Rome, Italy
- Biochemical and molecular characterization of the venom from the Cuban
scorpion Rhopalurus junceus, B.I. García-Gómez a, F.I.V. Coronas a, R. Restano-
Cassulini a, R.R. Rodríguez b, L.D. Possani a, *, a. Department of Molecular
Medicine and Bioprocesses, Instituto de Biotecnologia, Universidad Nacional
Autonoma de Mexico, Avenida Universidad, 2001, Apartado Postal 510-3,
Cuernavaca MOR. 62210, Mexico b. Centro de Desarrollo de la Montaña,
Ministerio de Ciencia, Tecnología y Medio Ambiente, Limonar de Monte Roux,
El Salvador Guantanamo, Cuba
GET A FREE TREATMENT PLAN
Regardless of your situation, we believe there is HOPE!
We understand that you may have many concerns right now.
Our admissions counselors are happy to help you find the answers you need.
Get a FREE personalized treatment plan today.
What To Expect
Fill out a secure and confidential form so we can get to know you a little better before the call.
– Less than 5 min to complete.
One of our admissions counselors will call you quickly to lend support and answer any questions that you may have about Hope4Cancer.